Integra LifeSciences (NASDAQ:IART) Releases Q4 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its fourth quarter earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $0.81-0.89 for the period, compared to the consensus estimate of $0.87. The company issued revenue guidance of $441-451 million, compared to the consensus revenue estimate of $448.48 million. Integra LifeSciences also updated its FY 2024 guidance to 2.410-2.490 EPS.

Integra LifeSciences Stock Performance

IART traded up $1.06 during mid-day trading on Wednesday, reaching $25.97. 261,435 shares of the company traded hands, compared to its average volume of 1,098,115. The stock has a market capitalization of $2.01 billion, a P/E ratio of 85.90, a P/E/G ratio of 0.66 and a beta of 1.08. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $45.42. The company’s fifty day moving average price is $18.77 and its 200-day moving average price is $24.38.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.02. The business had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company’s quarterly revenue was down .4% on a year-over-year basis. During the same period last year, the firm earned $0.76 earnings per share. On average, sell-side analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IART. Morgan Stanley increased their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research note on Monday, July 15th. Truist Financial lowered their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. JMP Securities reduced their price objective on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Finally, Bank of America cut their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $27.25.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.